Zevalin (In-111) IV
Generic Name: IBRITUMOMAB TIUXETAN - INJECTIONPronounced: (ih-brih-TOO-mow-mab tie-ooh-X-eh-tan)
Zevalin (In-111) IV Uses
This medication is combined with certain radioactive substances (Indium-111, Yttrium-90) and used along with rituximab to treat a certain type of cancer (B-cell non-Hodgkin's lymphoma) in patients whose cancer has returned or has not responded to other treatments. Ibritumomab tiuxetan and rituximab are known as monoclonal antibodies. They work by killing certain blood and cancer cells from your immune system (B cells). Yttrium-90 helps kill the cancer cells, and Indium-111 helps to show how the medication is spread throughout the body (imaging studies).
How To Use Zevalin (In-111) IV
This medication is given by injection into a vein by a health care professional. Follow all instructions for the proper handling and preparation of this product (e.g., precautions for radioactive substances). Do not shake the medication. Before using, check this product visually for particles or discoloration. Do not use the liquid if it is discolored. The medication may contain a few clear particles. The particles will not affect how well the medication works and will be removed by the filter. If you have any questions about the preparation or use of this medication, consult the pharmacist or doctor.
Dosage is based on your medical condition, weight, and response to treatment. This medication is usually given as 2 doses. It is always given within 4 hours after rituximab. The first dose of this medication is combined with Indium-111. A test is done usually 48 to 72 hours after your dose to determine how the medication has spread throughout the body. If the test shows that the medication has spread properly, another dose of this medication (combined with Yttrium-90) is given 7 to 9 days after the first dose.
